

16.1.5.1 SPONSOR

CLINICAL STUDY REPORT APPROVAL FORM

PROTOCOL NUMBER: C4591001

REPORT TITLE: Interim Report – Adolescents: A Phase 1/2/3, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of SARS-COV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Individuals

AUTHOR: Dzung Nguyen

I have reviewed this clinical study report, which is from its definitive source and final in content. I confirm that it is a complete and accurate representation of the relevant data and statistical analyses for this report.

Known deviations in the study did not impact overall compliance with Good Clinical Practice and local regulations.

Organization/Institution: BioNTech SE

Name/Position: Ugur Sahin, MD, Chief Executive Officer

Signature:  _____ **Date:** 13.04.21

090177e196c6a5da\Approved\Approved On: 14-Apr-2021 00:55 (GMT)

16.1.5.1 SPONSOR AGENT

CLINICAL STUDY REPORT APPROVAL FORM
--

PROTOCOL NUMBER: C4591001

REPORT TITLE: Interim Report – Adolescents: A Phase 1/2/3, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of SARS-COV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Individuals

AUTHOR: Dzung Nguyen

I have reviewed this clinical study report, which is from its definitive source and final in content. I confirm that it is a complete and accurate representation of the relevant data and statistical analyses for this report.

Known deviations in the study did not impact overall compliance with Good Clinical Practice and local regulations.

STATISTICS LINE HEAD: Kenneth Koury, PhD

CLINICAL LEAD: John L. Perez, MD, MBA, MA

090177e196be4e96\Approved\Approved On: 14-Apr-2021 02:26 (GMT)

Document Approval Record

Document Name: 16.1.5.1 - Sponsor Agent
Document Title: C4591001 Adolescents

Signed By:	Date(GMT)	Signing Capacity
Perez, John	13-Apr-2021 15:31:59	Final Approval
Koury, Kenneth	14-Apr-2021 02:26:15	Final Approval